Can Fite Biopharma Ltd - ESG Rating & Company Profile powered by AI
Alternative corporations in the scoring peer group for Can Fite Biopharma Ltd are displayedin the table. This report of Can Fite Biopharma Ltd was prepared by All Street Sevva using proprietary artificial intelligence. This article contains a Q&A table about Can Fite Biopharma Ltd.
Can Fite Biopharma Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | CK Life Sciences Intl (Holdings) Inc | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Can Fite Biopharma Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Can Fite Biopharma Ltd report the average age of the workforce?
Sign up for free to unlockDoes Can Fite Biopharma Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Can Fite Biopharma Ltd offer flexible work?
Sign up for free to unlockDoes Can Fite Biopharma Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Can Fite Biopharma Ltd conduct supply chain audits?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Can Fite Biopharma Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose water use targets?
Sign up for free to unlockDoes Can Fite Biopharma Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Can Fite Biopharma Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Can Fite Biopharma Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Can Fite Biopharma Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Can Fite Biopharma Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Can Fite Biopharma Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Can Fite Biopharma Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose its waste policy?
Sign up for free to unlockDoes Can Fite Biopharma Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose energy use targets?
Sign up for free to unlockDoes Can Fite Biopharma Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Can Fite Biopharma Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Can Fite Biopharma Ltd
These potential risks are based on the size, segment and geographies of the company.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.